DrAIStudio

Frontiers in Pharmacology call for papers

Current call-for-papers opportunities for Frontiers in Pharmacology. Ranking signals: Indexed (Active), JIF 4.8. Use the official publisher page to verify scope and submission rules.

Accepting CFPs for Frontiers in Pharmacology

Migrastatic Agents, Metastasis, and Mitochondrial Metabolism: Emerging Strategies for Cancer Drug Discovery

Deadline 2027-02-28FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Cancer remains one of the leading causes of death worldwide. Despite substantial progress in developing effective therapies over the past century, it remains...

Migrastatic Agents, Metastasis, and Mitochondrial Metabolism: Emerging Strategies for Cancer Drug Discovery

Deadline 2027-02-28FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Cancer remains one of the leading causes of death worldwide. Despite substantial progress in developing effective therapies over the past century, it remains...

Molecular basis of chemosensitivity

Deadline 2027-03-07FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Chemosensitivity — the degree to which cancer cells respond to therapeutic agents — remains one of the central determinants of treatment success in oncology....

Molecular basis of chemosensitivity

Deadline 2027-03-07FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Chemosensitivity — the degree to which cancer cells respond to therapeutic agents — remains one of the central determinants of treatment success in oncology....

Advances in Personalized Management of Patients with Airways Diseases

Deadline 2027-03-09FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Asthma and COPD remain leading causes of morbidity worldwide, and both are increasingly recognized as heterogeneous conditions encompassing multiple inflamma...

Advances in Personalized Management of Patients with Airways Diseases

Deadline 2027-03-09FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Asthma and COPD remain leading causes of morbidity worldwide, and both are increasingly recognized as heterogeneous conditions encompassing multiple inflamma...

Antimicrobial and Antiparasitic Drug Discovery: Experimental Pharmacology, Computational and AI/ML Approaches, and Translational Strategies

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Antimicrobial resistance is one of the defining health threats of our time. Drug-resistant bacteria, fungi, and parasites now undermine treatments that once ...

Computational Pharmacogenomics: Artificial Intelligence and Machine Learning for Variant Effect Prediction and Clinical Translation

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Over the past two decades, pharmacogenomics has shifted from common, coding variants in single populations toward genome-wide, cross-population analyses that...

Computational Pharmacogenomics: Artificial Intelligence and Machine Learning for Variant Effect Prediction and Clinical Translation

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Over the past two decades, pharmacogenomics has shifted from common, coding variants in single populations toward genome-wide, cross-population analyses that...

Fragment-Based Drug Discovery: Innovations, Challenges, and Translational Opportunities in Experimental Pharmacology

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Fragment-based drug discovery (FBDD) has rapidly evolved into a powerful approach for identifying and optimizing novel therapeutic agents. By using small, lo...

Fragment-Based Drug Discovery: Innovations, Challenges, and Translational Opportunities in Experimental Pharmacology

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Fragment-based drug discovery (FBDD) has rapidly evolved into a powerful approach for identifying and optimizing novel therapeutic agents. By using small, lo...

Institutional Implementation of Pharmacogenomics: Health Systems Policies, Barriers, and Best Practice Models

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Pharmacogenomics (PGx) offers a clinically actionable route to precision prescribing: by tailoring drug selection and dosing to an individual’s genetic profi...

Institutional Implementation of Pharmacogenomics: Health Systems Policies, Barriers, and Best Practice Models

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Pharmacogenomics (PGx) offers a clinically actionable route to precision prescribing: by tailoring drug selection and dosing to an individual’s genetic profi...

Pharmacogenomic Variability in Drug Metabolism: From Nuclear Receptors to Clinical Enzyme Regulation

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The regulation of drug-metabolizing enzymes (DMEs) is governed by nuclear receptors (NRs) — including PXR, CAR, AhR, FXR, and PPARα — that sense xenobiotic a...

Pharmacogenomic Variability in Drug Metabolism: From Nuclear Receptors to Clinical Enzyme Regulation

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The regulation of drug-metabolizing enzymes (DMEs) is governed by nuclear receptors (NRs) — including PXR, CAR, AhR, FXR, and PPARα — that sense xenobiotic a...

Protein Structure, Dynamics, and Function in Modern Drug Discovery

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Understanding how proteins fold, move, and interact with ligands sits at the heart of rational drug discovery. Advances in structural biology, including cryo...

Protein Structure, Dynamics, and Function in Modern Drug Discovery

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Understanding how proteins fold, move, and interact with ligands sits at the heart of rational drug discovery. Advances in structural biology, including cryo...

Real-World Safety Outcomes and Policy Responses to Adverse Drug Reactions

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Adverse drug reactions (ADRs) remain a major, and often preventable, source of patient harm even after drugs have received marketing authorization. In line w...

Real-World Safety Outcomes and Policy Responses to Adverse Drug Reactions

Deadline 2027-03-12FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Adverse drug reactions (ADRs) remain a major, and often preventable, source of patient harm even after drugs have received marketing authorization. In line w...

Artificial Intelligence in Drug Metabolism and Transport: From Multi-Omics Insights to Clinical and Pharmacological Validation

Deadline 2027-03-13FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Artificial intelligence (AI) is transforming pharmaceutical research by enabling the integration and interpretation of increasingly complex biological and ph...

Artificial Intelligence in Drug Metabolism and Transport: From Multi-Omics Insights to Clinical and Pharmacological Validation

Deadline 2027-03-13FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Artificial intelligence (AI) is transforming pharmaceutical research by enabling the integration and interpretation of increasingly complex biological and ph...

Nanoformulation Strategies to Overcome Multi-Drug Resistance in Cancer: From Pharmacological Characterization to Preclinical Translation

Deadline 2027-03-13FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Multi-drug resistance (MDR) remains the most formidable pharmacological barrier to effective cancer chemotherapy, accounting for treatment failure in the maj...

Nanoformulation Strategies to Overcome Multi-Drug Resistance in Cancer: From Pharmacological Characterization to Preclinical Translation

Deadline 2027-03-13FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Multi-drug resistance (MDR) remains the most formidable pharmacological barrier to effective cancer chemotherapy, accounting for treatment failure in the maj...

Volume II: Integrated PK/PD and Drug Metabolism Approaches in Drug Development and Evaluation

Deadline 2027-03-13FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Building on the success of Integrated PK/PD and Drug Metabolism Approaches in Drug Development and Evaluation, this Volume II continues to explore the essent...

Immunogenic Cell Death: From Mechanistic Insights to Pharmacological Intervention and Drug Discovery

Deadline 2027-03-14FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Immunogenic cell death (ICD) is a form of regulated cell death that not only eliminates stressed, damaged, or malignant cells but also actively alerts and en...

Immunogenic Cell Death: From Mechanistic Insights to Pharmacological Intervention and Drug Discovery

Deadline 2027-03-14FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Immunogenic cell death (ICD) is a form of regulated cell death that not only eliminates stressed, damaged, or malignant cells but also actively alerts and en...

Emerging Horizons of Metformin: Exploring Recent Advances and Addressing Challenges in Research and Clinical Utilization, Volume II

Deadline 2027-03-15FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Metformin remains one of the most widely prescribed oral biguanides for type 2 diabetes, yet its reach now extends far beyond glucose control. Research conti...

Emerging Horizons of Metformin: Exploring Recent Advances and Addressing Challenges in Research and Clinical Utilization, Volume II

Deadline 2027-03-15FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Metformin remains one of the most widely prescribed oral biguanides for type 2 diabetes, yet its reach now extends far beyond glucose control. Research conti...

Targeting Metabolic Reprogramming in Cancer: From Multi-Omics Signatures to Functional Pharmacology

Deadline 2027-03-16FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Cancer cells undergo extensive metabolic reprogramming to sustain proliferation, survival, invasion, and resistance to therapy. Beyond aerobic glycolysis, tu...

Targeting Metabolic Reprogramming in Cancer: From Multi-Omics Signatures to Functional Pharmacology

Deadline 2027-03-16FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Cancer cells undergo extensive metabolic reprogramming to sustain proliferation, survival, invasion, and resistance to therapy. Beyond aerobic glycolysis, tu...

Physicochemical and In Silico ADME Profiling of Gut Microbiota-Derived Metabolites: Bridging Computational Prediction and Experimental Validation

Deadline 2027-03-20FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The gut microbiota generates hundreds of structurally distinct bioactive metabolites whose physicochemical properties govern how they behave once they reach ...

Physicochemical and In Silico ADME Profiling of Gut Microbiota-Derived Metabolites: Bridging Computational Prediction and Experimental Validation

Deadline 2027-03-20FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The gut microbiota generates hundreds of structurally distinct bioactive metabolites whose physicochemical properties govern how they behave once they reach ...

Real-World Economic Evaluation of Advanced Therapy Medicinal Products After Market Access

Deadline 2027-03-22FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Advanced Therapy Medicinal Products (ATMPs), including gene therapies, cell-based therapies and tissue-engineered products, are transforming the therapeutic ...

Real-World Economic Evaluation of Advanced Therapy Medicinal Products After Market Access

Deadline 2027-03-22FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Advanced Therapy Medicinal Products (ATMPs), including gene therapies, cell-based therapies and tissue-engineered products, are transforming the therapeutic ...

Quantum Chemistry-Guided Design of Nitrogen-Containing Heterocycles as Anticancer Agents: From Reactivity Descriptors to Biological Validation

Deadline 2027-03-26FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Nitrogen-containing heterocycles, including pyrazoles, pyrimidines, isoxazoles, thiazoles, and naphthyridines, constitute the dominant structural class among...

Quantum Chemistry-Guided Design of Nitrogen-Containing Heterocycles as Anticancer Agents: From Reactivity Descriptors to Biological Validation

Deadline 2027-03-26FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Nitrogen-containing heterocycles, including pyrazoles, pyrimidines, isoxazoles, thiazoles, and naphthyridines, constitute the dominant structural class among...

Engineering Extracellular Communication: Glycan Interfaces, Extracellular Vesicles and Soluble Mediators for Integrative and Regenerative Pharmacology

Deadline 2027-04-15FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The secretome is more and more recognized as a dynamic communication system regulating tissue homeostasis, immune responses and regeneration. It comprises tw...

Engineering Extracellular Communication: Glycan Interfaces, Extracellular Vesicles and Soluble Mediators for Integrative and Regenerative Pharmacology

Deadline 2027-04-15FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The secretome is more and more recognized as a dynamic communication system regulating tissue homeostasis, immune responses and regeneration. It comprises tw...

Integrating Artificial Intelligence, Multi-Omics, and Nanomedicine to Target the Disease Immune Microenvironment

Deadline 2027-04-19FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The immune microenvironment plays a critical role in the progression and therapeutic resistance of a broad spectrum of diseases, most notably in cancers (suc...

Integrating Artificial Intelligence, Multi-Omics, and Nanomedicine to Target the Disease Immune Microenvironment

Deadline 2027-04-19FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The immune microenvironment plays a critical role in the progression and therapeutic resistance of a broad spectrum of diseases, most notably in cancers (suc...

Targeting Anion Channels and Associated Epithelial Ion Channels in Health and Disease: TMEM16/Anoctamins, ENaC, VRAC, and Beyond

Deadline 2027-04-26FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The TMEM16/anoctamin family, including ANO1, ANO2, ANO6, and ANO10, is increasingly recognized as a pharmacologically tractable class of proteins with calciu...

Structure-Dependent Toxicological Profiles of PFAS: Mechanistic Determinants, Predictive Models, and Organ-Specific Biomarkers

Deadline 2027-04-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Per- and polyfluoroalkyl substances (PFAS) comprise a structurally diverse class of thousands of compounds, sharing a persistent carbon-fluorine backbone but...

Structure-Dependent Toxicological Profiles of PFAS: Mechanistic Determinants, Predictive Models, and Organ-Specific Biomarkers

Deadline 2027-04-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Per- and polyfluoroalkyl substances (PFAS) comprise a structurally diverse class of thousands of compounds, sharing a persistent carbon-fluorine backbone but...

Targeting Neuroinflammation in Spinal Cord Injury: From Inflammatory Mechanisms to Pharmacological Interventions

Deadline 2027-04-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Spinal cord injury (SCI) triggers a devastating secondary neuroinflammatory cascade—driven by microglial activation, immune infiltration, and sustained pro-i...

Targeting Neuroinflammation in Spinal Cord Injury: From Inflammatory Mechanisms to Pharmacological Interventions

Deadline 2027-04-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Spinal cord injury (SCI) triggers a devastating secondary neuroinflammatory cascade—driven by microglial activation, immune infiltration, and sustained pro-i...

One Health Biotechnology Approaches to Infectious Disease Pharmacology: Emerging Bioactive Agents for Antimicrobial and Vector-Borne Disease Control

Deadline 2027-05-17FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The search for new anti-infectives increasingly looks to natural sources. However, producing and characterizing these compounds with clinical consistency rem...

One Health Biotechnology Approaches to Infectious Disease Pharmacology: Emerging Bioactive Agents for Antimicrobial and Vector-Borne Disease Control

Deadline 2027-05-17FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The search for new anti-infectives increasingly looks to natural sources. However, producing and characterizing these compounds with clinical consistency rem...

Rational Design of Safer Bioactive Scaffolds: Integrating Synthesis, Pharmacology, and Computational Toxicity Prediction

Deadline 2027-05-17FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Balancing therapeutic potency with organ safety remains a central challenge in medicinal chemistry, particularly for drugs targeting inflammation, cancer, an...

Rational Design of Safer Bioactive Scaffolds: Integrating Synthesis, Pharmacology, and Computational Toxicity Prediction

Deadline 2027-05-17FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Balancing therapeutic potency with organ safety remains a central challenge in medicinal chemistry, particularly for drugs targeting inflammation, cancer, an...

RNA Therapeutics in Clinical Translation: Oligonucleotides and RNA-Targeted Small Molecules From Discovery to Approved Drugs

Deadline 2027-05-21FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The past decade has transformed what a therapeutic molecule can be. mRNA, small interfering RNA (siRNA), and antisense oligonucleotide (ASO) drugs have moved...

RNA Therapeutics in Clinical Translation: Oligonucleotides and RNA-Targeted Small Molecules From Discovery to Approved Drugs

Deadline 2027-05-21FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

The past decade has transformed what a therapeutic molecule can be. mRNA, small interfering RNA (siRNA), and antisense oligonucleotide (ASO) drugs have moved...

Pharmacological Determinants of mRNA Vaccine Performance: RNA Chemistry, Lipid Nanoparticle Formulation, and Next-Generation Platforms

Deadline 2027-05-24FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

mRNA vaccines have moved from a largely theoretical platform to a clinically validated modality since the emergency authorizations of the first COVID-19 mRNA...

Pharmacological Determinants of mRNA Vaccine Performance: RNA Chemistry, Lipid Nanoparticle Formulation, and Next-Generation Platforms

Deadline 2027-05-24FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

mRNA vaccines have moved from a largely theoretical platform to a clinically validated modality since the emergency authorizations of the first COVID-19 mRNA...

Gut Microbiota as a Bridge: Deciphering the Mechanisms of Traditional Medicine through Microbiome-Metabolite Interactions

Deadline 2027-05-28FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Traditional medicines have long been valued for their therapeutic effects across a wide range of diseases, yet the precise molecular mechanisms underlying ma...

Gut Microbiota as a Bridge: Deciphering the Mechanisms of Traditional Medicine through Microbiome-Metabolite Interactions

Deadline 2027-05-28FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Traditional medicines have long been valued for their therapeutic effects across a wide range of diseases, yet the precise molecular mechanisms underlying ma...

Neuropharmacology of Alcohol Use Disorders

Deadline 2027-05-31FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Alcohol Use Disorder (AUD) remains a major global public health and socioeconomic challenge. Available pharmacotherapeutic agents show limited efficacy in re...

Neuropharmacology of Alcohol Use Disorders

Deadline 2027-05-31FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Alcohol Use Disorder (AUD) remains a major global public health and socioeconomic challenge. Available pharmacotherapeutic agents show limited efficacy in re...

Linking Human Pathophysiology with Advanced In Vitro Models for Regenerative and Delivery Focused Pharmacology

Deadline 2027-06-01FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Disease modeling is advancing alongside the broader adoption of New Approach Methodologies in biomedical research. Patient derived cells, induced pluripotent...

Linking Human Pathophysiology with Advanced In Vitro Models for Regenerative and Delivery Focused Pharmacology

Deadline 2027-06-01FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Disease modeling is advancing alongside the broader adoption of New Approach Methodologies in biomedical research. Patient derived cells, induced pluripotent...

Beyond Classical Monoamine Receptors: Emerging Regulators and Therapeutic Targets in Neuropharmacology

Deadline 2027-07-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Monoaminergic neurotransmission has traditionally been understood through the pharmacology of dopamine, serotonin, and adrenergic receptors. However, growing...

Beyond Classical Monoamine Receptors: Emerging Regulators and Therapeutic Targets in Neuropharmacology

Deadline 2027-07-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Monoaminergic neurotransmission has traditionally been understood through the pharmacology of dopamine, serotonin, and adrenergic receptors. However, growing...

Ethnopharmacology at 60: Sixty Years of Ethnopharmacology: From Local Knowledge to Global Recognition

Deadline 2027-09-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Ethnopharmacology can be traced to the interest in psychoactive and psychedelic substances in the 1960s; the term itself was first used in 1967 by Bo Holmste...

Ethnopharmacology at 60: Sixty Years of Ethnopharmacology: From Local Knowledge to Global Recognition

Deadline 2027-09-30FrontiersIndexed (Active)

Journal: Frontiers in Pharmacology

Ethnopharmacology can be traced to the interest in psychoactive and psychedelic substances in the 1960s; the term itself was first used in 1967 by Bo Holmste...

Reference integrity note: verify every citation against the original source before submission, including publication year, journal title, volume/issue, page range, DOI, and the target journal style.